PTO/SB/21 (05-03) Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE der the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application Number 10/633,762 TRANSMITTAL Filing Date August 4, 2003 **FORM** First Named Inventor Fred Hassan Art Unit 1614 (to be used for all correspondence after initial filing) **Examiner Name** Attorney Docket Number 00860.US1 Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance communication Fee Transmittal Form Drawing(s) to Group Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to Group Petition Amendment/Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a Proprietary Information After Final **Provisional Application** Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Terminal Disclaimer Extension of Time Request Identify below): A return-receipt postcard is enlosed. Request for Refund **Express Abandonment Request International Search Paper** CD, Number of CD(s) Information Disclosure Statement Remarks Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Individuat name Pharmacia & Upjohn Company Signature Date CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. Typed or printed name Julie K. Lyons

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

LeliEK

Signature

Date

February 18, 2004

					Atty. Docket No. 00860.US1			Serial No. 10/633,762							
			STOP!	s CITED BY	API	PLICANT					1				ı
LIST OFFREYERENCES CITED BY APPLICANT						Applicant Fred Hassan				Group					
FEB		(2)					Fili	ng Date	8/04/2003					-	
FEB	٠	X OF				TYCL DATE	L	OOCUMEN'	rs				Filing Da	ite	
SPICAT 8	TRADE	HIE				U.S. FAI1	T			Clas	ss S	ubclass	If Approp	riate	
	1	$\neg T$	Docum	ocument		Date		Name Melloni et al.		424	-	48.58			
Examine Initial	r		Number		January 8, 1979		M			564		349			
	1	AA.	4,229,449 5,068,433 5,391,735		June 11, 1990		Melloni et al.		54		174				
i	1	AB				April 12, 1994		Melloni et al.		$\frac{1}{51}$	-+	223.5			
	1	AC				April 12, 1331 April 28, 1995		Anthony S. dePadova				567			
	-	AD	5,75	3,651		July 21, 2000		Thomas J. Guttuso							
		AE	6,33	10,098B1	- 1	44 0000	1	Seth Ledern	nan	5	14	220	JAN.		
		AF	6,3	58,944B1		August 11, 2000	 v PA'	TENT DOCU	JMENTS		Class	Subcla			
							N PATENT DOCUMENTS Country			1	Jiaas				
		T		cument		Date									
			N	umber						1	A61K	31/00			
		_			-	June 22, 2000		World			A61K	31/13	3		
		AC	^	VO 01/01973A		November 6, 200	01	World			A61K	-	8		
		Al		VO 02/40006		March 15, 2002		World			C07I		/10		
		A			21 2002		World			A61					
		A	- 1	WO 03/00069		November 5, 20	world				AUIII		00	in St.	Ting.
-		1	K	WO 03/03959		1 97	7 2002 World								
-		1	AL	WO 03/04975	24A1	November 27, THER PRIOR AR	T (Inc	luding Author,	Title, Date, Pertir	ent Pag	ges, Etc.		misms in m	enopausal	not
-															
H		T	AM	XP-0011767	34 R 0 No	November 21, THER PRIOR AR obert R. Freedman 2(August) 1998.			o roises the sv	veatin	g thres	hold in	symptomati	c but not ir	١
				VD 001176	742 F	Robert R. Freedma	n et	al., "Clonidin Fertility a	nd Sterility, V	74 No.	1 (Jul	y) 2000.	medicir	ne-news.cor	n.
AM XP-001176734 Robert R. Freedman, PhD," Biochemical, in Freedman, PhD, Biochemical, in Free									W W .III		_				
+			AO												
VP 002936123 "Reboxetine", 1999 00 01								ess in O	LOIOBIO						
AQ XP-008025613 "Hot Flushes: Mechanism and 1989, Alan R. Liss, Inc.															
									Oncologist	,					
AR C. L. Loprinzl et al, "Venlafaxine in Management of Hotology of Controlled Trial", The Lancet V356 December 16, 2000. Controlled Trial", The Lancet V356 December 16, 2000. Kathleen L. Pritchard, "Hormone Replacement in Women with a History of Breast Cancer" The 2001;6:353-362. AT Richard M. Goldberg et al, "Transdermal Clonidine for Ameliorating Tamoxifen-Induced Hot Fl															

OLES	EOF REFI	ERENCES CITED BY APPLICANT Use several sheets if necessary)		Docket No. 0860.US1	Serial No. 10/633,762				
ر ' ا	3 2004 3		Applicant Fred Hassan						
FEB L	MART		Filing Date	8/04/2003	Group				
G TR.	Clinical Oncology V12 No. 1 (January), 1994 155-158.								
,	AU	AU Larry R. Laufer et al, "Effect of Clonidine on Hot Flashes in Postmenopausal Women", V60 No.5(Nove 1982.							
	AV B.E. Leonard, "Noradrenaline in basic models of depression", European Neuropsychopharmacology 7 Suppl 1997 S11-S16.								
	herapy of Hot Flashes in 381.								
	AX V. Stearns et al, "A Pilot Trial Assessing the efficacy of Paroxetine Hydrochloride (Paxil) in controlling hot in breast cancer survivors", Annals of Oncology 11: 17, 2000.								
Exami	ner		Date Considered						